Last ¥6,640 JPY
Change Today -80.00 / -1.19%
Volume 274.9K
4536 On Other Exchanges
As of 1:00 AM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

santen pharmaceutical co ltd (4536) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/4/14 - ¥7,130
52 Week Low
02/4/14 - ¥4,065
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SANTEN PHARMACEUTICAL CO LTD (4536)

Related News

No related news articles were found.

santen pharmaceutical co ltd (4536) Related Businessweek News

No Related Businessweek News Found

santen pharmaceutical co ltd (4536) Details

Santen Pharmaceutical Co., Ltd. is engaged in the research, development, manufacture, and marketing of ophthalmic and anti-rheumatic pharmaceuticals for the protection and enhancement of eyesight and health. The company offers various prescription pharmaceuticals in the areas, such as corneal and conjunctival epithelial disorders; glaucoma; retinal and uveal disorders; ocular infections/allergy; and rheumatoid arthritis. It also provides over-the-counter pharmaceuticals; and medical devices, such as intraocular lenses and injectors. Santen Pharmaceutical Co., Ltd. offers its products in Japan, rest of Asia, Europe, and North America. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

3,072 Employees
Last Reported Date: 06/25/14
Founded in 1890

santen pharmaceutical co ltd (4536) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

santen pharmaceutical co ltd (4536) Key Developments

Santen Pharmaceutical Co., Ltd. and the Singapore Eye Research Institute Collaborate to Develop New Ophthalmology Therapeutics

Santen Pharmaceutical Co. Ltd. and the Singapore Eye Research Institute have announced a multi-year collaboration to develop new therapeutics in ophthalmology, with a focus on diseases prevalent in Asia.

Santen Pharmaceutical Co. Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2014; Provides Earnings Guidance for the Full Year Ending March 31, 2015; Announces Interim Dividend for the Fiscal 2015; Provides Final Dividend Guidance for the Fiscal 2015

Santen Pharmaceutical Co. Ltd. reported consolidated earnings results for the six months ended September 30, 2014. For the period, net sales were JPY 71,925 million against JPY 69,263 million a year ago. Operating income was JPY 13,194 million against JPY 14,457 million a year ago. Ordinary income was JPY 13,602 million against JPY 14,861 million a year ago. Net income was JPY 9,099 million against JPY 8,994 million a year ago. Net income per share was JPY 110.16 against JPY 108.99 a year ago. Diluted net income per share was JPY 109.74 against JPY 108.68 a year ago. The company announced the interim dividend of JPY 50.00 per share and expects to pay final dividend of JPY 50.00 per share. For the full year ending March 31, 2015, the company expects to report net sales of JPY 156,000 million, operating income of JPY 30,000 million, ordinary income of JPY 30,000 million and net income of JPY 19,500 million or net income per share of JPY 236.26.

Santen Opens Subsidiary in Italy

Santen to open a subsidiary in Italy. Santen will set up a dedicated commercial team that will enable the firm to boost promotion of its product portfolio, including Saflutan (tafluprost) and Cosopt (dorzolamide).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4536:JP ¥6,640.00 JPY -80.00

4536 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4536.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4536 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANTEN PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at